KV Pharmaceutical | St. Louis Public Radio

KV Pharmaceutical

KV Emerges From Bankruptcy

Sep 16, 2013

KV Pharmaceutical Company announced Monday that its reorganization plan is in effect, and it has emerged from bankruptcy.

Based in Bridgeton, the company filed for bankruptcy Aug. 4, 2012.

KV is primarily focused on women’s healthcare, but the company has had struggles in recent years.

That includes a failed lawsuit against the FDA, which refused to prevent competitors from selling a much lower cost version of Makena.

KV initially charged as much as $1,500 for a dose of Makena, which is meant to  reduce the risk of premature births.

Former KV Pharmaceutical CEO pleads guilty to misbranding drugs

Mar 10, 2011
e-MagineArt.com | Flickr

The former chairman and CEO of St. Louis-based KV Pharmaceutical Co. has pleaded guilty to two federal charges of misbranding drugs.

The U.S. Attorney's office says that 69-year-old Marc S. Hermelin entered the pleas Thursday. He was sentenced to one month in prison and a $1 million fine and agreed to forfeit $900,000 to the federal government.

KV Pharmaceutical manufactured generic prescription drugs, including a pain relief and opiate drug called morphine sulfate.

This article first appeared in the St. Louis Beacon, Dec.12, 2008 - On the job for barely two weeks, David Van Vliet faces the task of restoring KV Pharmaceutical's reputation on Wall Street and in Washington.

Named interim CEO on Dec. 5, Van Vliet is trying to mollify analysts, who have complained for years about insufficient corporate communication. And he's trying to satisfy regulators, who have periodically -- and emphatically -- chastised the practices of the Brentwood-based maker of generic drugs and brand-name medications.